Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,143
- Phase 21,065
- Phase 1821
- Phase 1/Phase 2445
- Phase 3424
- Phase 4238
- Phase 2/Phase 394
Top conditions
- Multiple Sclerosis341
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis141
- Type 1 Diabetes133
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals63
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California494
- Maryland196
- Alabama175
- Florida143
- Arizona140
- New York123
- Massachusetts119
- Texas118
- Illinois81
- Colorado77
Recruiting studies6,230 total
- NCT05745285Recruiting
LLS care support program for blood cancer patients
This study looks at whether LLS services and support improve outcomes and the day-to-day experience of care for people with leukemia, lymphoma, myeloma, MDS, or MPN. It’s mainly about matching you to the right support and following your progress for 6 months.
Miami, FloridaAges 18 years+ - NCT05745714RecruitingPhase 1/Phase 2
Targeted triple-combination treatment for children with relapsed blood cancers
This Phase 1/2 study tests a multi-drug combination (ruxolitinib, venetoclax, dexamethasone, plus chemotherapy) for children whose blood cancer has come back or did not respond. It aims to reduce the cancer by targeting specific genetic changes and may offer a new option when standard treatments have not worked.
ViennaAges 1–21 - NCT05746039RecruitingPhase 1/Phase 2
Testing semaglutide for advanced lung disease
This study checks whether semaglutide is safe and feasible for people with advanced lung diseases and higher body weight. It may help by testing a structured treatment approach, but it includes several health and safety limits.
Philadelphia, PennsylvaniaAges 18–80 - NCT05746078Recruiting
Testing elastic threads to lift mild to moderate facial sagging
This trial tests the safety and performance of a special “elastic thread” treatment used to lift facial drooping (mild to moderate ptosis) in people who may or may not have had prior cosmetic treatments. You may benefit by getting the study treatment, but you would need to follow the visit schedule and rules of the study.
CréteilAges 35–75 - NCT05748015Recruiting
Checking how the nervous system is affected in multiple sclerosis
This study looks at signs of how your automatic “control” nerves (the autonomic nervous system) may be affected in people with multiple sclerosis. It may help researchers better understand different types of MS and how to recognize nervous-system involvement.
Telese Terme, BeneventoAges 18 years+ - NCT05749094Recruiting
Ultrasound of the optic nerve in new suspected giant eye artery disease
This trial studies whether a quick ultrasound of the optic nerve (plus an eye exam) can help evaluate new suspected giant cell arteritis (GCA). It may help doctors assess eye risk early and decide on the best next steps.
London, OntarioAges 50–99 - NCT05750498Recruiting
Study to improve outcomes in autoimmune liver disease
This trial tests approaches to improve health outcomes for people with autoimmune liver diseases. It includes specific autoimmune conditions affecting the liver and bile ducts, and it may help your care team learn what works best for these illnesses.
Palo Alto, CaliforniaAges Any age - NCT05751044RecruitingPhase 1/Phase 2
Study of four medicines for children with difficult blood cancers
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
ViennaAges 1–21 - NCT05751447Recruiting
Studying immune cells in suspected sarcoidosis
This study looks at immune cells in the lungs, lymph nodes, and blood to learn more about suspected sarcoidosis. You may benefit by helping researchers better understand the condition and by getting close medical evaluation as part of the study.
StockholmAges 18–90 - NCT05751798RecruitingPhase 1/Phase 2
Test drug OSE-279 for advanced lung cancer that has no key mutations
This Phase 1/2 study tests how well and how safely OSE-279 works in people with advanced non-small cell lung cancer (NSCLC) who cannot be cured with surgery or radiation. It also looks at the right dose and how it may help, especially if the tumor has high PD-L1.
AnderlechtAges 18 years+ - NCT05754593Recruiting
Study ovarian reserve in women with multiple sclerosis
This study compares egg supply (“ovarian reserve”) in women with multiple sclerosis to women without MS. It may help doctors understand how MS affects reproductive health and egg supply.
BordeauxAges 25–35 - NCT05754710Recruiting
Kids taking Xeljanz for juvenile arthritis study
This study is collecting real-world information about how Xeljanz (tofacitinib) is used and how well it works in children with juvenile idiopathic arthritis. It may help improve how the medicine is used safely in everyday care.
SeoulAges 2–17 - NCT05756179RecruitingPhase 3
Diosmin and hesperidin for mild to moderate rheumatoid arthritis
This trial tests whether two natural plant-based medicines (diosmin and hesperidin) can reduce symptoms in people with mild to moderate rheumatoid arthritis. It compares treatment outcomes to standard care to see if these supplements help control the disease.
AlexandriaAges 19–65 - NCT05757219RecruitingPhase 2
Itacitinib before CAR T for aggressive B-cell lymphoma
This trial tests itacitinib given before CAR T cell therapy to see if it can improve outcomes for people with diffuse large B-cell lymphoma (DLBCL). It may help by calming certain immune signals before CAR T is started.
Tampa, FloridaAges 18 years+ - NCT05758532RecruitingPhase 4
Modified measles vaccine schedule to help prevent allergies in babies
This study tests whether changing the measles vaccine timing in 6-month-old children can reduce allergy risk and also help protect against unrelated infections. If your child is already up to date with routine vaccines, they may be eligible for a modified measles (MMR) schedule used in the trial.
GenevaAges 6 months–6 months - NCT05758610RecruitingPhase 1
Study drug test for relapsed or hard-to-treat AML and NHL
This Phase 1 trial tests ETH-155008, a new medicine, in adults with relapsed or refractory acute myeloid leukemia (AML) or non-Hodgkin lymphoma (NHL). It’s mainly designed to see how the treatment works in the body and whether it may help when standard treatment isn’t available or hasn’t worked.
Zhengzhou, HenanAges 18 years+ - NCT05758831RecruitingPhase 3
Rituximab vs ocrelizumab for relapsing multiple sclerosis
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
Lyon, BronAges 18–55 - NCT05759793RecruitingPhase 1
CAR T trial for relapsed myeloma targeting GPRC5D
This Phase 1 trial tests a CAR T-cell treatment made to find a specific marker called GPRC5D on myeloma (or plasma cell leukemia) cells. It may help people whose disease has returned or hasn’t responded to several prior treatments.
ShanghaiAges 18–75 - NCT05760898Recruiting
Helping control blood pressure in people with rheumatoid arthritis
This study aims to improve blood pressure control in adults who have both uncontrolled high blood pressure and rheumatoid arthritis. It may help by testing ways to better coordinate care between primary care and rheumatology.
Durham, North CarolinaAges 18 years+ - NCT05762705Recruiting
Mobile game app to help you take PrEP
This trial tests whether a mobile gaming app can help people stick with PrEP (HIV prevention) so doses aren’t missed. It may help you stay on track during the first month after starting or restarting PrEP.
Boston, MassachusettsAges 15–34 - NCT05765812RecruitingPhase 1/Phase 2
Debio 0123 with temozolomide for recurrent or new glioblastoma
This early-phase study tests Debio 0123 (an anticancer medicine) combined with temozolomide, and for newly diagnosed patients also with radiation. It aims to see whether this treatment combination can slow or control glioblastoma in adults.
Chicago, IllinoisAges 18 years+ - NCT05767047RecruitingPhase 3
Apremilast study for children with mouth ulcers from Behçet’s
This trial studies whether apremilast can help reduce mouth ulcers in children who have Behçet’s disease or juvenile psoriatic arthritis. You may be considered if your child finished a main study and is under 18, and can safely continue treatment.
ThessalonikiAges 5–18 - NCT05767450Recruiting
Test for early type 1 diabetes in children
This study looks at children who have just started insulin for new-onset type 1 diabetes. It aims to test an intervention early in the course of the disease, which may help change how the immune system and diabetes progress.
Milan, MilanAges 7–17 - NCT05768399Recruiting
Study uses blood or test markers to track childhood asthma
This study looks for biological “markers” that may help explain why asthma starts and how it changes over time in children. It may help your child’s doctors understand asthma better, especially for diagnosis or tracking.
Chongqing, Chongqing MunicipalityAges 4–12
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,742 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.